Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 9/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897551 | 0.81 | ALDH1A1 (0.42) | KMT2AHPGDMEN1MGLLSMN1; SMN2 | |
| SCHEMBL2900034 | 0.79 | NPC1 (0.44) | SMN1; SMN2 | |
| SCHEMBL2903061 | 0.79 | HCAR1 (0.42) | KCNN4HCAR1MGLL | |
| SCHEMBL1903586 | 0.79 | MAPK14 (0.40) | KCNN4HCAR1KMT2AMEN1MGLL | |
| SCHEMBL316519 | 0.73 | RAB9A (0.41) | KMT2ASMN1; SMN2RXFP1 | |
| SCHEMBL1906253 | 0.70 | ALDH1A1 (0.40) | KMT2AHPGDMEN1MGLLSMN1; SMN2 | |
| SCHEMBL1902421 | 0.69 | FAAH (0.42) | KMT2AMEN1MGLLSMN1; SMN2RXFP1 | |
| SCHEMBL2900762 | 0.68 | HCAR1 (0.41) | HCAR1MGLLSCN9A | |
| SCHEMBL1906555 | 0.68 | ALDH1A1 (0.38) | HCAR1KMT2AMEN1 | |
| SCHEMBL17144796 | 0.67 | MAPK14 (0.48) | KCNN4KMT2AHPGDMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | KCNN4 4505/4885HCAR1 2490/4885KMT2A 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.